Eltrombopag (Promacta)

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search

General information

Class/mechanism: Thrombopoietin (TPO) receptor agonist; interacts with the transmembrane domain of the TPO-receptor to trigger downstream signal cascades that ultimately stimulate platelet production by promoting proliferation and differentiation of megakaryocytes from bone marrow progenitor cells.[1][2][3]
Route: PO
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

History of changes in EMA indication

  • 2010-03-11: Initial authorization as Revolade

History of changes in PMDA indication

  • 2017-08-25: New additional indication and a new dosage for the treatment of aplastic anemia.

Also known as

  • Code name: SB-497115-GR
  • Generic name: eltrombopag olamine
  • Brand names: Eltrom, Promacta, Revolade